ENZN — Enzon Pharmaceuticals Balance Sheet
0.000.00%
- $11.13m
- -$34.86m
- 68
- 54
- 43
- 55
Annual balance sheet for Enzon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 5.45 | 48.1 | 47.6 | 47 | 47 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.485 | 0.031 | 0.028 | 0 | — |
Total Other Current Assets | |||||
Total Current Assets | 5.99 | 48.2 | 47.8 | 47.4 | 47.3 |
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 6.48 | 48.2 | 47.8 | 47.6 | 47.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.423 | 0.412 | 0.403 | 1.7 | 1.71 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.423 | 0.412 | 0.403 | 1.7 | 1.71 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 6.05 | 47.8 | 47.4 | 45.9 | 46 |
Total Liabilities & Shareholders' Equity | 6.48 | 48.2 | 47.8 | 47.6 | 47.7 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |